Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company dedicated to cancer prevention, particularly focusing on patients with gastroesophageal reflux disease (GERD). GERD, commonly known as chronic heartburn or acid reflux, places millions at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Lucid's groundbreaking products, EsoCheck and EsoGuard, are at the forefront of early detection and prevention.
EsoGuard is a bisulfite-converted Next Generation Sequencing (NGS) DNA assay performed on surface esophageal cells collected with the EsoCheck device. This test quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), detecting esophageal precancer and cancer with over 90% sensitivity and specificity. EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device. This device can sample surface esophageal cells in less than five minutes, providing an effective, non-invasive alternative to costly and invasive endoscopy.
Lucid has shown substantial progress, including solid revenue growth on stable test volumes. Their revenue cycle management processes are improving, and the CYFT program targeting specific groups like firefighters is thriving. Their direct contracting initiative is also accelerating, with near-term prospects for delivering contracts, testing, and revenue.
Recently, Lucid announced a partnership with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Public service videos run on Nasdaq's billboard in Times Square, spreading awareness about the link between heartburn and esophageal cancer.
Lucid's peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored study confirmed the high sensitivity and specificity of the EsoGuard test. This significant milestone supports their goal of widespread screening and early detection, moving towards Medicare coverage.
Lucid continues to advance its operations and strategies, recently closing a $30 million preferred stock financing to support their growth. They are on track to achieve key milestones, including expanded private and public coverage and direct contracting. Lucid's clinical evidence base for EsoGuard is robust, further enhancing their line of sight to Medicare coverage.
For more information, visit www.luciddx.com and their parent company PAVmed at www.pavmed.com.
Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and PAVmed subsidiary, announces a business update conference call and webcast scheduled for November 13, 2024, at 8:30 AM ET. Chairman and CEO Lishan Aklog will provide operational updates and growth strategy insights, while CFO Dennis McGrath will present Q3 2024 financial results.
The webcast will be accessible through the company's investor relations website at luciddx.com. U.S. callers can dial 1-800-836-8184, and international callers 1-646-357-8785, referencing 'Lucid Diagnostics Business Update' to join. A 30-day replay will be available on the company website afterward.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method of using methylation of the cyclin-A1 (CCNA1) gene to detect esophageal precancer and cancer. This patent strengthens Lucid's intellectual property portfolio and protects a key component of its EsoGuard® Esophageal DNA Test.
EsoGuard uses next-generation sequencing to assess DNA methylation at 31 sites on two genes, vimentin (VIM) and CCNA1. The association of CCNA1 methylation with esophageal neoplasia is novel and appears to be more specific than VIM methylation. The technology behind EsoGuard and the EsoCheck® Esophageal Cell Collection Device was developed at Case Western Reserve University, with Lucid holding the exclusive worldwide license to commercialize it.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event will feature a fireside chat with Dennis McGrath, Lucid's Chief Financial Officer, scheduled for Tuesday, October 15, 2024, at 11:30 AM Eastern Time.
Interested parties can attend the virtual fireside chat by visiting the provided link. Following the conference, a recording of the session will be available on Lucid's investor relations website. This participation demonstrates Lucid's commitment to engaging with investors and sharing insights about their cancer prevention diagnostics business.
Lucid Diagnostics (Nasdaq: LUCD) announced its participation in The MedTech Conference 2024, scheduled for October 15-17 in Toronto, Canada. The company will showcase its EsoGuard® and EsoCheck® technologies in the conference's Innovation Pavilion, offering live demonstrations to attendees. Lishan Aklog, M.D., Lucid's Chairman and CEO, will participate in a CEOs Unplugged event alongside industry leaders. Additionally, Shaun O'Neil, Lucid's President and COO, will deliver the company's presentation at the conference's Investor Forum.
Lucid's presence at the conference, organized by AdvaMed, provides an opportunity to engage with industry leaders, potential partners, and investors. The event is expected to attract over 1,500 companies and attendees from 45 countries, highlighting its significance in the medical technology industry.
Lucid Diagnostics Inc. (Nasdaq: LUCD) held its inaugural #CheckYourFoodTube Precancer Testing Event for former NFL players in Cincinnati, Ohio. The initiative aims to raise awareness about the link between chronic heartburn and esophageal cancer, and promote EsoGuard® Esophageal DNA Test for precancer detection. The event included an educational session and on-site testing for at-risk former NFL players.
Solomon Wilcots, former Cincinnati Bengals player, emphasized the importance of early detection and encouraged fellow athletes to take proactive steps. Dr. Lishan Aklog, Lucid's CEO, highlighted the opportunity to prevent esophageal cancer through awareness and testing. Lucid plans to expand these events to other cities nationwide, targeting former NFL players and their fans who have risk factors such as heartburn, age over 50, male gender, white race, obesity, smoking, or family history.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced that its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer will be highlighted at the American Foregut Society's (AFS) 2024 Annual Meeting from September 26-28, 2024. Dr. Dan Lister, AFS President-elect, will lead a session titled "Finding Barrett's - Time to Ditch the Scope?" discussing EsoGuard as a non-invasive alternative to screening upper endoscopy.
This follows the AFS's recent open letter advocating for medical policy coverage of EsoGuard by commercial payors, emphasizing its strong scientific evidence and incorporation in AFS physicians' practices. The session will explore EsoGuard's role in triaging at-risk patients and enabling efficient use of endoscopy resources for early detection and prevention of esophageal cancer.
PAVmed Inc. (Nasdaq: PAVM) announced efforts to regain compliance with Nasdaq's listing requirements, including the deconsolidation of Lucid Diagnostics (Nasdaq: LUCD) from PAVmed's financial statements. This move will no longer reflect Lucid's operating losses in PAVmed's consolidated financials, while maintaining PAVmed's holdings of Lucid common stock. The deconsolidation is part of a series of steps to address Nasdaq's determination that PAVmed had not met continued listing standards for 180 consecutive days.
PAVmed also announced board changes, including the appointment of Dr. Sundeep Agrawal, a seasoned biotech investor, to replace departing directors. The company will request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, expected in October.
Lucid Diagnostics (Nasdaq: LUCD) announced its participation as the sole Diamond Sponsor at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress in Edinburgh, Scotland, from September 22-24, 2024. The company will showcase its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer.
Lucid will host a symposium on Non-Endoscopic Screening for Barrett's Esophagus, chaired by experts Dr. Vani Konda and Dr. Nicholas Shaheen. The panel discussion will include Dr. Vivek Kaul and Dr. Rehan Haidry. This event highlights Lucid's commitment to being a leading voice in esophageal cancer prevention through early detection of precancer.
The ISDE World Congress is a global platform for collaboration and knowledge exchange among experts in esophageal diseases, covering topics such as diagnostics, novel therapies, and latest advancements in the field.
Lucid Diagnostics (Nasdaq: LUCD) has signed a memorandum of understanding (MOU) with Front Line Mobile Health to enhance early detection of esophageal cancer in firefighters. The collaboration aims to expand patient access to Lucid's EsoGuard® Esophageal DNA test through co-marketing initiatives. Firefighters face a 62% higher risk of developing esophageal cancer, making this partnership important for their health and safety.
The MOU builds on Lucid's previous collaboration with Front Line, which facilitated a major #CheckYourFoodTube Precancer Testing Event. By leveraging Front Line's resources and expertise in caring for firefighters, Lucid aims to increase access to esophageal precancer testing and drive revenue through contracted high-volume testing events.
Lucid Diagnostics, a subsidiary of PAVmed, has published an analytical validation study of its EsoGuard® Esophageal DNA test in the peer-reviewed journal Diagnostics. The study demonstrates excellent analytical performance of the EsoGuard assay on samples collected with the EsoCheck® Esophageal Cell Collection Device for diagnosing esophageal precancer (Barrett's Esophagus) and esophageal adenocarcinoma.
Key findings include:
- 89% analytical sensitivity
- 100% analytical specificity
- 96% analytical accuracy
- 100% inter- and intra-assay precision
EsoGuard uses next-generation sequencing to detect DNA methylation at 31 sites on two genes associated with conditions along the BE-EAC spectrum. This study complements EsoGuard's existing clinical validity and utility evidence base.
FAQ
What is the current stock price of Lucid Diagnostics (LUCD)?
What is the market cap of Lucid Diagnostics (LUCD)?
What is Lucid Diagnostics Inc.?
What are EsoCheck and EsoGuard?
Why are GERD patients at risk?
How does EsoGuard work?
What recent achievements has Lucid Diagnostics announced?
What partnerships has Lucid Diagnostics formed?
What are the financial highlights for Lucid Diagnostics?
What is the significance of the NCI-sponsored study?
How does Lucid's technology compare to traditional methods?
What are Lucid's future plans?
